ATE332902T1 - 3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika - Google Patents

3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika

Info

Publication number
ATE332902T1
ATE332902T1 AT02723011T AT02723011T ATE332902T1 AT E332902 T1 ATE332902 T1 AT E332902T1 AT 02723011 T AT02723011 T AT 02723011T AT 02723011 T AT02723011 T AT 02723011T AT E332902 T1 ATE332902 T1 AT E332902T1
Authority
AT
Austria
Prior art keywords
antiarrhythmics
formulations
Prior art date
Application number
AT02723011T
Other languages
English (en)
Inventor
Christina Hovdal
Anna Lundgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE332902T1 publication Critical patent/ATE332902T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02723011T 2001-04-12 2002-04-12 3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika ATE332902T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101329A SE0101329D0 (sv) 2001-04-12 2001-04-12 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ATE332902T1 true ATE332902T1 (de) 2006-08-15

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02723011T ATE332902T1 (de) 2001-04-12 2002-04-12 3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika

Country Status (26)

Country Link
US (1) US20050037067A1 (de)
EP (1) EP1389212B1 (de)
JP (1) JP2005500262A (de)
KR (1) KR20030088498A (de)
CN (1) CN1514839A (de)
AR (1) AR035806A1 (de)
AT (1) ATE332902T1 (de)
BG (1) BG108234A (de)
BR (1) BR0208828A (de)
CA (1) CA2443473A1 (de)
CZ (1) CZ20032774A3 (de)
DE (1) DE60213084T2 (de)
EE (1) EE200300495A (de)
HU (1) HUP0303486A3 (de)
IL (1) IL158033A0 (de)
IS (1) IS6989A (de)
MX (1) MXPA03009209A (de)
NO (1) NO20034529L (de)
NZ (1) NZ528561A (de)
PL (1) PL366629A1 (de)
RU (1) RU2003129230A (de)
SE (1) SE0101329D0 (de)
SK (1) SK12562003A3 (de)
TW (1) TWI257391B (de)
WO (1) WO2002083689A1 (de)
ZA (1) ZA200307756B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2979698A4 (de) * 2013-03-29 2016-11-16 Astellas Pharma Inc Pharmazeutische zusammensetzung zur oralen verabreichung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (de) * 1987-09-24 1989-04-06 Basf Ag Bispidinderivate als klasse iii-antiarrhythmika
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
RU2254333C2 (ru) * 1999-04-09 2005-06-20 Астразенека Аб Производные адамантана, способ их получения, фармацевтическая композиция на их основе и способы лечения
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
RU2003129230A (ru) 2005-04-10
EE200300495A (et) 2003-12-15
SK12562003A3 (sk) 2004-03-02
MXPA03009209A (es) 2004-01-29
JP2005500262A (ja) 2005-01-06
CZ20032774A3 (cs) 2004-01-14
EP1389212A1 (de) 2004-02-18
CN1514839A (zh) 2004-07-21
HUP0303486A3 (en) 2005-04-28
DE60213084T2 (de) 2007-01-11
US20050037067A1 (en) 2005-02-17
HUP0303486A2 (hu) 2004-01-28
SE0101329D0 (sv) 2001-04-12
ZA200307756B (en) 2005-01-03
WO2002083689A1 (en) 2002-10-24
BG108234A (bg) 2005-04-30
EP1389212B1 (de) 2006-07-12
BR0208828A (pt) 2004-03-09
TWI257391B (en) 2006-07-01
IS6989A (is) 2003-10-10
DE60213084D1 (de) 2006-08-24
AR035806A1 (es) 2004-07-14
PL366629A1 (en) 2005-02-07
NZ528561A (en) 2005-03-24
KR20030088498A (ko) 2003-11-19
NO20034529L (no) 2003-12-08
CA2443473A1 (en) 2002-10-24
IL158033A0 (en) 2004-03-28
NO20034529D0 (no) 2003-10-09

Similar Documents

Publication Publication Date Title
DE60131971D1 (de) 1,3,8-TRIAZA-SPIROi4,5 DECAN-4-ONDERIVATIVE ALS NEUROKININREZEPTORANTAGONISTEN
BR0216099B1 (pt) "conjunto de desgaste".
DE60213276D1 (de) 1,2,4-thiadiazoliumverbindungen als melanocortinrezeptor-modulatoren
ATE323095T1 (de) 3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika
NO20040654L (no) Gassmikrosfaere-liposomkompositter.
NO20040387L (no) Nedihullsfrigjoringskopling.
MXPA03009315A (es) 1.3-dionas carbociclicas tiazolil-substituidas como agentes pesticidas.
ATE332902T1 (de) 3,7-diazabicycloc3.3.1)-formulierungen als antiarrhythmika
EG23207A (en) Novel fungicidal compositions based on propamocarsand pyridylmethylbenzamide derivatives.
ITTO20020747A1 (it) Composizione.
ITTO20020745A1 (it) Composizione.
ES1048400Y (es) Bota-patin mejorada.
DE50214487D1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen
BR0103827B1 (pt) cola - pds.
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
ES1050491Y (es) Chupete infantil.
BR8101236Y1 (pt) desensiladeira.
ATA2452001A (de) Löffelbagger, insbesondere spiel- bzw. spielzeug-löffelbagger
ITTO20020746A1 (it) Composizione.
ES1048499Y (es) Persiana compacta.
ES1057516Y (es) Pieza rodapie mejorada.
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður
ES1053113Y (es) Tenedor-expulsor.
ES1048703Y (es) Conversor.
ES1048140Y (es) Calcetin-zapato.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties